SGO Annual Meeting | Conference

Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer

March 15th 2017

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Dr. Altman on Neoadjuvant Chemotherapy in High-Grade Serous Carcinoma

March 15th 2017

Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma.

Carboplatin Hypersensitivity Linked to BRCA Deficiency in Ovarian Cancer

March 14th 2017

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer

March 14th 2017

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

Niraparib Effective in Ovarian Cancer, Regardless of BRCA Status

March 14th 2017

The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of BRCA status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.

Dr. Brown on Genetic Counseling for Breast and Ovarian Cancer

March 14th 2017

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer

March 14th 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

Parents Continue to See HPV Vaccine as Unnecessary and Worry Over Its Safety

March 14th 2017

A survey was given to parents of teenage girls in an effort to understand the relatively low uptake of the HPV vaccine in the United States.

Tumor Gene Methylation May Predict Ovarian Cancer Response to Rucaparib

March 13th 2017

Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib (Rubraca).

Gynecologic Oncologists Cite Time, Money as Barriers to Global Health Participation

March 13th 2017

Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology in National Harbor, MD.

Dr. Barber on Surgical Readmission and Survival in Ovarian Cancer

March 13th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

Dr. Swisher on Next Steps of Treatment for Ovarian Cancer

March 13th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer.

New Insights Into Rucaparib Activity in Ovarian Cancer

March 13th 2017

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.

Ovarian Cancer Study Fails to Settle Debate Over Chemotherapy Regimens

April 22nd 2016

Intraperitoneal therapy was not superior to intravenous treatment when used in combination with bevacizumab (Avastin) as a regimen for patients with advanced ovarian cancer.

Targeted Drug Falls Short Versus Paclitaxel for Ovarian Cancer

March 22nd 2016

Weekly paclitaxel for recurrent ovarian cancer prevailed over the VEGF inhibitor cabozantinib in a randomized comparison of the two drugs.

Trial of Ovarian Chemotherapy Regimens Fails to Provide Clarity

March 22nd 2016

Three different chemotherapy regimens, each combined with bevacizumab, failed to demonstrate an advantage for patients with advanced ovarian cancer or build on results of a landmark trial reported more than a decade ago.

Phase III Studies Aim to Expand Olaparib's Ovarian Cancer Approval

March 22nd 2016

Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.

Dr. Jean Hurteau on Diagnosing Ovarian Clear Cell Carcinoma

March 21st 2016

Jean Hurteau, MD, professor, Division of Gynecologic Oncology at NorthShore University Health System, discusses the difficulties of diagnosing ovarian clear cell carcinoma. Hurteau says data for the diagnosis of the carcinoma is older, and is not relevant to contemporary diagnoses due to the fact that there were more mixed tumors previously than there are now.

Dr. Bobbie J. Rimel on Genetic Testing in Ovarian Cancer

March 21st 2016

Bobbie J. Rimel, MD, assistant professor, Obstetrics and Gynecology, discusses discovering BRCA mutations early in ovarian cancer patients. Rimel says with the genetic information of knowing which patients harbor which genetic mutations, oncologists can offer their patients treatments such as PARP inhibitors, which are gene-specific.

Trial Tests Combo of Pexidartinib and Pembrolizumab in Ovarian and Other Solid Tumors

March 21st 2016

An ongoing clinical trial has begun the process of evaluating whether the addition of a booster agent can take the anticancer activity of PD-1 directed immunotherapy to another level.